Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of nosocomial infections, with an increasing prevalence worldwide. Researchers aimed to apply a new approach called “pseudo-natural product” (PNP) scaffolds for antibacterial development, and hypothesized that the indotropane class of PNPs might show potential activity against bacterial strains.